Current Report Filing (8-k)
November 29 2018 - 3:51PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act
of 1934.
Date of Report: November
28, 2018
(Date of earliest event reported)
BioVie Inc.
|
(Exact name of registrant as specified in its charter)
|
Nevada
|
|
000-55292
|
|
46-2510769
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification Number)
|
|
|
11601 Wilshire Blvd., Suite 1100, Los Angeles, CA
|
|
90025
|
(Address of principal executive offices)
|
|
(Zip Code)
|
(312) 283-5793
(Registrant’s telephone number,
including area code)
Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an
emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b–2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended
transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the
Exchange Act. ☐
Item 8.01 Other Events
On November 28, 2018, BioVie Inc.
(“BioVie”)
issued a press release announcing that the U.S. Food and Drug Administration had granted an Orphan Drug designation to Biovie for
terlipressin for the treatment of hepatorenal syndrome. A copy of the press release is provided as Exhibit 99.1 to this Current
Report.
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: November 29,
2018
|
|
|
|
BIOVIE INC.
|
|
|
|
|
|
|
|
|
|
|
By:
|
|
/
s/ Jonathan Adams
|
|
|
|
|
|
|
|
Jonathan Adams
|
|
|
|
|
|
|
|
President & Chief Operating Officer
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
EXHIBIT INDEX
Exhibit Number
|
|
Description
|
|
99.1
|
|
|
Press Release of BioVie Inc. dated November 28, 2018
|